Intersection · Clinical × chronic kidney disease
Clinical topics tagged chronic kidney disease
Topics in Clinical carrying the tag chronic kidney disease. Renal outcomes and dose considerations.
35 topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Adolescents: a distinct evidence base
Adolescents: a distinct evidence base Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The published trials in this…
|
3 | 11k | 9h | |
|
About the Comorbidities category
Type 2 diabetes, hepatic steatosis, sleep apnoea, cardiovascular and renal disease. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
4 | 16k | 12h | |
|
Osteoarthritis and mechanical versus metabolic improvement
Osteoarthritis and mechanical versus metabolic improvement Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…
|
+2 | 6 | 30k | 12h |
|
Type 2 diabetes and the largest part of the evidence base — does this still hold?
Type 2 diabetes and the largest part of the evidence base — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about a population rather…
|
+17 | 22 | 4.5k | 1d |
|
Athletes in weight-category sports: a different risk calculus
Athletes in weight-category sports: a different risk calculus — setting out what I have, and where I think it stops being reliable. General question, not a request for advice about my own care — I know the…
|
+38 | 42 | 6.6k | 1d |
|
PCOS and metabolic overlap: what is and is not studied
On the subject in the title: PCOS and metabolic overlap: what is and is not studied Working notes rather than a conclusion. Asking about a population rather than about a person. The published trials in this…
|
3 | 6.6k | 1d | |
|
Osteoarthritis and mechanical versus metabolic improvement — one year on
On the subject in the title: Osteoarthritis and mechanical versus metabolic improvement — one year on Working notes rather than a conclusion. General question, not a request for advice about my own care — I…
|
+52 | 56 | 8.1k | 15d |
|
Gastro-oesophageal reflux: improving or worsening?
The question in the title: Gastro-oesophageal reflux: improving or worsening? I will give what I have already checked below so nobody repeats it. Asking about a population rather than about a person. The…
|
+54 | 58 | 8.2k | 1mo |
|
Type 2 diabetes and the largest part of the evidence base
Posting this under the heading it deserves: Type 2 diabetes and the largest part of the evidence base Everything below is what sits behind that. General question, not a request for advice about my own care —…
|
+81 | 89 | 2.9k | 3mo |
|
Pregnancy and pregnancy planning: contraindication and washout
Posting this under the heading it deserves: Pregnancy and pregnancy planning: contraindication and washout Everything below is what sits behind that. General question, not a request for advice about my own…
|
+111 | 122 | 2.4k | 3mo |
|
Adolescents: a distinct evidence base — one year on
Posting this under the heading it deserves: Adolescents: a distinct evidence base — one year on Everything below is what sits behind that. General question, not a request for advice about my own care — I know…
|
+78 | 88 | 9.3k | 3mo |
|
Older adults, sarcopenia risk, and the trade-off nobody quantifies
Older adults, sarcopenia risk, and the trade-off nobody quantifies — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published…
|
+103 | 109 | 12k | 5mo |
|
Cardiovascular risk: reading the outcome trials as a set
Cardiovascular risk: reading the outcome trials as a set Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The published…
|
4 | 12k | 5mo | |
|
Second pass at: Pregnancy and pregnancy planning: contraindication and washout
Second pass at: Pregnancy and pregnancy planning: contraindication and washout Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a…
|
+111 | 127 | 1.6k | 6mo |
|
Hepatic steatosis: what the MASH trial evidence supports — one year on
On the subject in the title: Hepatic steatosis: what the MASH trial evidence supports — one year on Working notes rather than a conclusion. General question, not a request for advice about my own care — I…
|
2 | 4.1k | 6mo | |
|
Older adults, sarcopenia risk, and the trade-off nobody quantifies — the long version
Older adults, sarcopenia risk, and the trade-off nobody quantifies — the long version — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a…
|
+64 | 69 | 15k | 7mo |
|
History of disordered eating and why it changes the conversation
History of disordered eating and why it changes the conversation Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…
|
+20 | 24 | 30k | 8mo |
|
Revisiting: Gallbladder disease risk with rapid weight loss
Revisiting: Gallbladder disease risk with rapid weight loss Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…
|
2 | 2k | 9mo | |
|
Hypertension improvement and when medication needs revisiting
Hypertension improvement and when medication needs revisiting Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…
|
+74 | 79 | 1.1k | 10mo |
|
Hepatic impairment and the absence of data
Hepatic impairment and the absence of data — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published trials in this class mostly…
|
+30 | 35 | 32k | 10mo |
|
Follow-up: History of disordered eating and why it changes the conversation
Posting this under the heading it deserves: History of disordered eating and why it changes the conversation Everything below is what sits behind that. General question, not a request for advice about my own…
|
+75 | 81 | 23k | 10mo |
|
[2026 update] Cardiovascular risk: reading the outcome trials as a set
Posting this under the heading it deserves: Cardiovascular risk: reading the outcome trials as a set Everything below is what sits behind that. Asking about a population rather than about a person. The…
|
+99 | 103 | 32k | 11mo |
|
Older adults, sarcopenia risk, and the trade-off nobody quantifies — does this still hold?
Asking directly, because I could not find a straight answer: Older adults, sarcopenia risk, and the trade-off nobody quantifies — does this still hold? General question, not a request for advice about my own…
|
2 | 22k | 11mo | |
|
Hepatic steatosis: what the MASH trial evidence supports
Hepatic steatosis: what the MASH trial evidence supports — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published trials in…
|
+77 | 83 | 950 | 13mo |
|
Obstructive sleep apnoea and a hard endpoint in this class
On the subject in the title: Obstructive sleep apnoea and a hard endpoint in this class Working notes rather than a conclusion. Asking about a population rather than about a person. The published trials in…
|
+120 | 129 | 1.8k | 13mo |
|
[2026 update] Gastro-oesophageal reflux: improving or worsening?
Asking directly, because I could not find a straight answer: Gastro-oesophageal reflux: improving or worsening? General question, not a request for advice about my own care — I know the difference and I would…
|
3 | 782 | 13mo | |
|
Second pass at: Obstructive sleep apnoea and a hard endpoint in this class
Second pass at: Obstructive sleep apnoea and a hard endpoint in this class — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The…
|
2 | 726 | 14mo | |
|
Revisiting: Heart failure with preserved ejection fraction: symptom endpoints
On the subject in the title: Revisiting: Heart failure with preserved ejection fraction: symptom endpoints Working notes rather than a conclusion. General question, not a request for advice about my own care…
|
+4 | 8 | 43k | 17mo |
|
Coming back to: Renal impairment: what the labelling says about dose
Renal impairment: what the labelling says about dose — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published trials in this…
|
+30 | 34 | 48k | 18mo |
|
Gallbladder disease risk with rapid weight loss
Posting this under the heading it deserves: Gallbladder disease risk with rapid weight loss Everything below is what sits behind that. General question, not a request for advice about my own care — I know the…
|
+56 | 63 | 34k | 18mo |
Sponsored
Janoshik Analytical — independent third-party testingHPLC purity and mass-spectrometric identity on submitted samples, reported with the method stated. The laboratory most often cited in this community’s verification records.Independent testing →
Sponsored
GL Biochem (Shanghai) Ltd. — synthesis, directFounded 1998. ISO 9001 and cGMP certified, over 1,500 staff and 200-plus patents. Custom peptide synthesis and amino acid derivatives, with a batch certificate on every order.Custom synthesis →